Showing 4631-4640 of 5646 results for "".
- Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patients-with-dry-eye-disease/2478661/Palatin Technologies announced positive results in its phase 2 study of PL9643 for the treatment of dry eye disease (DED). Statistically significant improvement in multiple signs and symptoms was achieved in the moderate to severe patient population after 2 weeks of dosing and at the 12-week visi
- Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitishttps://modernod.com/news/nicox-initiates-phase-2b-trial-of-ncx-4251-a-potential-first-in-class-treatment-for-blepharitis/2478662/Nicox SA announced the initiation of the Mississippi trial, a phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis. NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystal
- Regenxbio Announces Dosing of First Patient in Phase 2 ALTITUDE Trial of RGX-314 for the Treatment of DRhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-altitude-trial-of-rgx-314-for-the-treatment-of-dr/2478651/Regenxbio announced that the first patient has been dosed in ALTITUDE, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR). “We are pleased to announce the first patient dosed in our ALTITUDE tr
- Alsanza Announces Global Launch of Alsee Zero Glistening, Zero Haze Hydrophobic Monofocal IOLhttps://modernod.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/Germany-based Alsanza announced the launch of the Alsee Zero Glistening Zero Haze Hydrophobic Monofocal IOL. The Alsee IOL is developed and designed to provide long-term clarity and high-contrast sensitive quality of vision with its 24-hour aspheric optic design. Alsee Zero Glistening Zero
- EyeQue to Launch VisionCheck 2 Do-It-Yourself Smartphone Vision Testhttps://modernod.com/news/eyeque-to-launch-visioncheck-2-do-it-yourself-smartphone-vision-test/2478648/EyeQue announced the upcoming launch of EyeQue VisionCheck 2, a refraction device available for consumers to test their own vision and order new glasses from home. VisionCheck 2 is a lightweight optical smartphone attachment and mobile app. The test results are expr
- GenSight Biologics Announces Publication of Results from Lumevoq REVERSE Pivotal Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-3-trial/2478644/GenSight Biologics announced that the journal Science Translational Medicine has published results from the REVERSE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate stu
- No Red Flags in FDA Review of Pfizer, BioNTech’s COVID-19 Vaccine Candidatehttps://modernod.com/news/no-red-flags-in-fda-review-of-pfizer-biontechs-covid-19-vaccine-candidate/2478641/In briefing documents released Tuesday ahead of an FDA advisory committee meeting on December 10, agency staff said that efficacy data submitted by Pfizer and BioNTech in support of BNT162b2 are “consistent” with recommendations previously detailed in guidance on the emergency-use aut
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/Aldeyra Therapeutics announced enrollment of the first patient in the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multicenter randomized, double-masked, parallel design, vehicle-controlled clinical trial will assess the effica
- Biden Builds Out Health Team with Xavier Becerra Named to Lead HHShttps://modernod.com/news/biden-builds-out-health-team-with-xavier-becerra-named-to-lead-hhs/2478635/US President-elect Joe Biden released more of his health team picks on Monday, nominating California Attorney General Xavier Becerra to serve as Secretary of Health and Human Services (HHS). In addition, Vivek Murthy, who was the US Surgeon General from 2014 to 2017, has been selected to return t
- Katena Products Announces Steve Blazejewski as New CEOhttps://modernod.com/news/katena-products-announces-steve-blazejewski-as-new-ceo/2478633/Katena Products announced that Steve Blazejewski has joined as Chief Executive Officer. As a seasoned executive, Mr. Blazejewski brings impressive leadership experience and medical device knowledge to Katena. He has previously served as President of Medical Solutions at Cardinal Health and